Nguyen Maxime, Kabbout Valentin, Berthoud Vivien, Gounot Isabelle, Dransart-Raye Ophélie, Douguet Christophe, Bouchot Olivier, Morgant Marie-Catherine, Bouhemad Belaid, Guinot Pierre-Grégoire
Department of Anaesthesiology and Intensive Care, Dijon University Hospital, Dijon, France.
University of Burgundy and Franche-Comté, Dijon, France.
Can J Anaesth. 2022 Jul;69(7):859-867. doi: 10.1007/s12630-022-02259-4. Epub 2022 May 2.
Veno-venous extracorporeal membrane oxygenation (vvECMO) is a highly invasive technique with a high risk of mortality. Based on reports of improved outcomes in high-volume ECMO centers, we established a regional vvECMO unit. The objective of this study was to evaluate how the vvECMO unit affected patient mortality rates.
This was a historical cohort study of all patients admitted to Dijon University Hospital and supported by vvECMO between January 2011 and June 2021. Patients managed with the vvECMO unit were compared with patients managed with non-vvECMO units. The primary outcome was 90-day mortality.
Of 172 patients treated using vvECMO, 69% were men, and the median [interquartile range] age was 59 [48-66] yr. Of the 172 patients, 35 were treated in the vvECMO unit and 137 were treated elsewhere (110/137 before the unit was established and 27/137 after). Ninety-day mortality was lower in patients managed in the vvECMO unit (15/35, 43% vs 92/137, 67%; P = 0.005). Within the vvECMO unit, mortality rates were also lower for the subgroup of patients managed after the specialized unit was established (15/35, 43% vs 20/27, 74%; P = 0.002). After adjusting for baseline severity of illness at vvECMO initiation, the vvECMO unit was independently associated with a lower 90-day mortality rate (hazard ratio, 0.41; 95% confidence interval, 0.21 to 0.80).
The establishment of a vvECMO unit was associated with reduced 90-day mortality. This improved survival may relate to patient selection, more specialized mechanical ventilation support, and/or improvement of vvECMO care.
静脉-静脉体外膜肺氧合(vvECMO)是一项具有高死亡风险的高侵入性技术。基于大容量ECMO中心预后改善的报道,我们设立了一个区域vvECMO治疗单元。本研究的目的是评估vvECMO治疗单元如何影响患者死亡率。
这是一项对2011年1月至2021年6月间入住第戎大学医院并接受vvECMO支持的所有患者进行的历史性队列研究。将在vvECMO治疗单元接受治疗的患者与在非vvECMO治疗单元接受治疗的患者进行比较。主要结局是90天死亡率。
在172例接受vvECMO治疗的患者中,69%为男性,年龄中位数[四分位间距]为59[48 - 66]岁。在这172例患者中,35例在vvECMO治疗单元接受治疗,137例在其他地方接受治疗(该治疗单元设立前110/137例,设立后27/137例)。在vvECMO治疗单元接受治疗的患者90天死亡率较低(15/35,43%对92/137,67%;P = 0.005)。在vvECMO治疗单元内,在专门治疗单元设立后接受治疗的患者亚组死亡率也较低(15/35,43%对20/27,74%;P = 0.002)。在对vvECMO启动时的基线疾病严重程度进行调整后,vvECMO治疗单元与较低的90天死亡率独立相关(风险比,0.41;95%置信区间,0.21至0.80)。
vvECMO治疗单元的设立与90天死亡率降低相关。这种生存改善可能与患者选择、更专业的机械通气支持和/或vvECMO护理的改善有关。